ProMis shares tumble after competitor's Alzheimer trial failure, CEO calls reaction overblown
read at STAT ↗Negative
ProMis Neurosciences, developer of an amyloid‑targeting Alzheimer’s therapy, saw its stock plunge sharply last week.
The decline came after Acumen Pharmaceuticals announced that its own amyloid‑targeting drug failed to demonstrate cognitive or functional benefit in a mid‑stage study.
ProMis CEO Neil Warma described the market move as a "complete overreaction," emphasizing that Acumen’s setback does not automatically predict the fate of ProMis’s candidate.
source
This writeup was produced by pharmadog from original reporting by STAT.
Original headline: “STAT+: A closer look at ProMis Neurosciences and its Alzheimer’s drug”
read at STAT ↗517 words · retrieved 3h ago
comments(0)
5-min edit window · permanent after that